Konstantin Taganov

Company: Blacksmith Medicines

Job title: Vice President, Discovery

Seminars:

Novel FEN1 Inhibitor with Unique Metal-Binding Pharmacophore to Enhance Synergistic Therapeutic Effects with USP1, PARP, PARG, & ATR Inhibitors 9:00 am

Highlighting the discovery of BSM-1516, a novel and highly potent FEN1 inhibitor, demonstrating significant selectivity and efficacy, especially against HR-deficient cancer cells—a breakthrough overcoming previous chemistry limitations Presenting evidence of strong synergy between BSM-1516 and multiple DDR drug classes (e.g., PARP, PARG, USP1, ATR inhibitors), underscoring its potential to enhance the therapeutic effects of existing…Read more

day: Day Two